William Díaz and Lisa Peterson wrote this bylined article analyzing FTC challenges to pharmaceutical industry mergers, particularly those involving consent orders that require divestitures to a buyer identified up-front. “Pharmaceutical or biotechnology companies considering transactions should analyze the competitive aspects of the products at issue and should carefully consider the relevant factors discussed to gauge whether the FTC is likely to challenge any aspect of the proposed transaction,” the authors wrote. Read the full article (subscription required).
